• 1
    Abbott KC, Bucci JR, Matsumoto CS et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 29082918.
  • 2
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 3
    Neumann UP, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226231.
  • 4
    Berenguer M. Outcome of posttransplantation hepatitis C virus disease—Is it the host, the virus, or how we modify the host and/or the virus? Liver Transpl 2002; 8: 889891.
  • 5
    Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 6
    Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy. Transplantation 2005; 79: 261268.
  • 7
    Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843861.
  • 8
    Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799805.
  • 9
    Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005; 5: 139144.
  • 10
    Roth D, Reddy R, Kupin W et al. Long-term impact of HCV on clinical outcomes and liver histology in kidney recipients [abstract]. Am J Transplant 2004; 2: 289.
  • 11
    Kamar N, Rostaing L, Selves J et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 17041712.
  • 12
    Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 11711175.
  • 13
    Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 13841392.
  • 14
    Masini M, Campani D, Boggi U et al. Hepatitis C virus infection and human pancreatic β-cell dysfunction. Diabetes Care 2005; 28: 940941.
  • 15
    Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 14991508.
  • 16
    Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol 2005; 79: 50065016.
  • 17
    Delgado-Borrego A, Casson D, Schoenfeld D et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004; 77: 703710.
  • 18
    Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus. Transplantation 2003; 75: SS3SS24.
  • 19
    Khalili M, Lim WJ, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 2004; 10: 349355.
  • 20
    Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 10661072.
  • 21
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178185.
  • 22
    Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 13: 13741380.
  • 23
    Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680687.
  • 24
    Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after α-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 20922098.
  • 25
    Abbott KC, Lentine KL, Bucci JR et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol 2004; 15: 31663174.
  • 26
    John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8: 708713.
  • 27
    Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 12821288.
  • 28
    Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 73: 775782.
  • 29
    Wiessner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group 2. Transplantation 1998; 66: 493499.
  • 30
    Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63S66.
  • 31
    Akalin E, Murphy B, Sehgal V, Ames S, Daly L, Bromberg JS. Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients. Clin Transplant 2004; 18: 384389.
  • 32
    Zekry A, Gleeson M, Guey S, McCaughan GW. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 5257.